Aethlon Medical (AEMD) Stock Price, News & Analysis

Company Overview

Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components. Aethlon has advanced the device through human clinical trials, exploring its potential in patients with viral infections—such as hepatitis C and COVID-19—and in oncology patients where tumor‐derived exosomes contribute to immune system evasion. The company continues to refine its technology, pursue regulatory designations, and seek strategic collaborations to expand its clinical development efforts.

Headquartered in San Diego, California, Aethlon Medical was established with a mission to bring innovative extracorporeal therapies to market. Under the leadership of President and Chief Executive Officer Phillip D. Borden, the company engages with regulatory agencies and research institutions across North America and internationally. Aethlon’s research and development operations are complemented by partnerships aimed at accelerating the clinical evaluation of its platform and ultimately delivering new treatment options for patients with urgent medical needs.

Key Stats

• Today's Range: $2.18 to $2.37
• 50-Day Range: $1.65 to $2.39
• 52-Week Range: $1.36 to $35.20
• Volume: 155,457 shs
• Average Volume: 28,197 shs
• Market Capitalization: $3.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Aethlon Medical Stock Analysis - MarketRank™

Aethlon Medical scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Aethlon Medical has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Aethlon Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aethlon Medical are expected to grow in the coming year, from ($9.94) to ($0.98) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aethlon Medical is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aethlon Medical is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aethlon Medical has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.90% of the float of Aethlon Medical has been sold short.

Short Interest Ratio / Days to Cover

Aethlon Medical has a short interest ratio ("days to cover") of 1.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aethlon Medical has recently decreased by 59.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aethlon Medical does not currently pay a dividend.

Dividend Growth

Aethlon Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Aethlon Medical this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for AEMD on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aethlon Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.71% of the stock of Aethlon Medical is held by insiders.

Percentage Held by Institutions

1.99% of the stock of Aethlon Medical is held by institutions.

Company Calendar

• Last Earnings: 2/12/2026
• Today: 5/12/2026
• Next Earnings (Estimated): 6/25/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - HMO
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:AEMD
• CIK: 882291
• Web: www.aethlonmedical.com
• Phone: (858) 459-7800
• Fax: N/A
• Employees: 10
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): ($14.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.39 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -219.39%
• Return on Assets: -164.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.68
• Quick Ratio: 5.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $25.52 per share
• Price / Book: 0.09

Miscellaneous

• Outstanding Shares: 1,570,000
• Free Float: 1,558,000
• Market Cap: $3.44 million
• Optionable: No Data
• Beta: 1.50